<VariationArchive RecordType="classified" VariationID="831943" VariationName="NC_000012.12:g.(?_51913089)_(51916243_?)del" VariationType="Deletion" Accession="VCV000831943" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-05" DateCreated="2020-04-15" MostRecentSubmission="2020-04-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="820507" VariationID="831943">
      <GeneList>
        <Gene Symbol="ACVRL1" FullName="activin A receptor like type 1" GeneID="94" HGNC_ID="HGNC:175" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q13.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="51906944" stop="51923361" display_start="51906944" display_stop="51923361" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52301201" stop="52317144" display_start="52301201" display_stop="52317144" Strand="+" />
          </Location>
          <OMIM>601284</OMIM>
          <Haploinsufficiency last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000012.12:g.(?_51913089)_(51916243_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>12q13.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" innerStart="52306873" innerStop="52310027" display_start="52306873" display_stop="52310027" variantLength="3155" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.(?_52306873)_(52310027_?)del" Assembly="GRCh37">
            <Expression>NC_000012.11:g.(?_52306873)_(52310027_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000012.12:g.(?_51913089)_(51916243_?)del AND Telangiectasia, hereditary hemorrhagic, type 2" Accession="RCV001032466" Version="1">
        <ClassifiedConditionList TraitSetID="2259">
          <ClassifiedCondition DB="MedGen" ID="C1838163">Telangiectasia, hereditary hemorrhagic, type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-11-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-11-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2020-04-15">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16690726</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20414677</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20501893</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22028876</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22799562</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22718755</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23653583</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26176610</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2259" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3671" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Osler Weber Rendu syndrome type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Telangiectasia, hereditary hemorrhagic, type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Telangiectasia, hereditary hemorrhagic, type 2</ElementValue>
                <XRef ID="MONDO:0010880" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HHT2</ElementValue>
                <XRef Type="MIM" ID="600376" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ORW2</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are characteristically found on the lips, tongue, buccal and gastrointestinal (GI) mucosa, face, and fingers. The appearance of telangiectases is generally later than epistaxis but may be during childhood. Large AVMs occur most often in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. A minority of individuals with HHT have GI bleeding, which is rarely seen before age 50 years.</Attribute>
                <XRef ID="NBK1351" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000515716" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500010" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509788" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512240" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515719" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000241591" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000511258" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528531" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528884" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9901" />
                <XRef ID="9901" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301525</ID>
                <ID Source="BookShelf">NBK1351</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="HHT Foundation Int'l, 2011">
                <ID Source="PubMed">19553198</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Shovlin et al., 2000">
                <ID Source="PubMed">10751092</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="HHT Foundation Int'l, 2020">
                <ID Source="PubMed">32894695</ID>
              </Citation>
              <XRef ID="774" DB="Orphanet" />
              <XRef ID="C1838163" DB="MedGen" />
              <XRef ID="MONDO:0010880" DB="MONDO" />
              <XRef Type="MIM" ID="600376" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2357028" SubmissionDate="2020-02-06" DateLastUpdated="2020-04-15" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="6480794|MedGen:C1838163" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001195773" DateUpdated="2020-04-15" DateCreated="2020-04-15" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-11-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26176610</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20501893</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23653583</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16690726</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22718755</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22028876</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20414677</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22799562</ID>
          </Citation>
          <Comment>This variant is an in-frame deletion of the genomic region encompassing exons 3-8 of the ACVRL1 gene. It preserves the integrity of the reading frame. This variant has been observed to segregate with hereditary haemorraghic telangiectasia (HHT) in a family (PMID: 23653583) and detected in an unrelated individuals with HHT (PMID: 16690726, 20414677). This variant affects a cysteine residue located within the ACVRL1 protein ectodomain. Cysteine residues in this domain of ACVRL1 are involved in the formation of disulfide bridges critical for protein structure and stability (PMID: 22028876, 22718755, 22799562). In addition, missense substitutions within the ACVRL1 ectodomain affecting cysteine residues are overrepresented in patients with HHT (PMID: 20501893, 26176610 and www.hhtmutation.org). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ACVRL1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.(?_52306873)_(52310027_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Hereditary hemorrhagic telangiectasia type 2</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C1838163" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2357028" TraitType="Disease" MappingType="Name" MappingValue="Hereditary hemorrhagic telangiectasia type 2" MappingRef="Preferred">
        <MedGen CUI="C1838163" Name="Telangiectasia, hereditary hemorrhagic, type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

